Fluoroquinolones: Difference between revisions
No edit summary |
|||
| Line 13: | Line 13: | ||
**Hyper/hypoglycemia | **Hyper/hypoglycemia | ||
**Hematologic toxicity | **Hematologic toxicity | ||
** | **Depression/Suicidality | ||
*Black box warning from US FDA | *Black box warning from US FDA | ||
** | **Tendonitis and tendon rupture<ref>Gültuna S. et al. Ciprofloxacin induced tendinitis. J Clin Rheumatol. 2009;15 (4): 201-2</ref> | ||
**Peripheral Neuropathy<ref>Food and Drug Administration: Drug safety announcement about fluoroquinolones and possible peripheral neuropathy [http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf PDF]</ref> | **Peripheral Neuropathy<ref>Food and Drug Administration: Drug safety announcement about fluoroquinolones and possible peripheral neuropathy [http://www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf PDF]</ref> | ||
{{Template:Clinically Utilized Antibiotics}} | {{Template:Clinically Utilized Antibiotics}} | ||
| Line 25: | Line 22: | ||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
==External Links== | |||
*[http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm126085.htm FDA info for Health Professionals] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:ID]] | [[Category:ID]] | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 00:02, 16 November 2018
Indications
- UTI (2nd line)
- Prostatitis
- Chlamydia
- PID
- Traveler's Diarrhea
Adverse Effects
- Common adverse effects
- GI and neuro toxicity
- Rash
- QT prolongation
- Hyper/hypoglycemia
- Hematologic toxicity
- Depression/Suicidality
- Black box warning from US FDA
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||